The Food and Drug Administration extended the approval of the oral anticancer drug for the treatment of patients with the most common sort of liver cancer, Bayer said.
The drug has already been approved in Europe for the treatment of liver cancer, and has been approved since 2005 for the treatment of advanced kidney cancer in more than 60 countries including the U.S. and the European Union.
"This milestone will likely establish Nexavar as the standard systemic therapy for the treatment of liver cancer and is a turning point in improving treatment outcomes in patients facing the devastating impact of this disease," said Arthur Higgins, chairman of Bayer HealthCare AG.
Bayer shares were down 0.2 percent at Ђ53.92 (US$79.09) in Frankfurt trading.
There are legitimate authorities in Donetsk and Luhansk republics now, with which Russia can implement the project of the economic integration of the Donbass
Russia has been developing an energy module on the basis of the megawatt-class nuclear power plant since 2010. The spaceship needs neither sunlight nor solar batteries